miR-1267 Induces Tumorigenicity and Contributes to Risk of Clear Cell Renal Cell Carcinoma

Yıl 2019, Cilt: 5 Sayı: 2, 100 - 105, 28.08.2019

Sercan Ergün , Kalbiye Konanç

https://doi.org/10.19127/mbsjohs.569404

Öz

Objective: Dysregulated microRNA signatures in different cancer
types are being uncovered continually implying their significance in cancer
pathogenesis. miR-1267 was not previously associated with RCC. In this
study, it is aimed to obtain the expression profile of miR-1267 in patients
with ccRCC and its correlation with patient parameters.

Methods:
Kidney Cancer cDNA Array consisting of cDNA samples obtained from healthy
kidney tissues of 4 healthy individuals and tumoral kidney tissues of 5 Stage
I, 5 Stage II, 3 Stage III and 2 Stage IV ccRCC patients was used. Hsa-miR-1267
and SNORD48 (as housekeeping gene) expressions were analyzed. miR-1267
expression was statistically correlated with the clinical parameters of
patients. miRGator 3.0 database was used to compare miR-1267 expression
patterns of different urological cancer types.

Results:
The expression of miR-1267 was significantly higher in male than female
(p=0.027). Also, there were statistically significant increase in miR-1267
expression in stage IV when compared to stage I (p<0.001). Moreover,
increased platelet/lymphocyte ratio and calcium level, which were parameters
giving information about the occurrence of ccRCC, are significantly associated
with increased miR-1267 expression (p<0.001 and p=0.003, respectively). The expression of miR-1267 in kidney tumor tissues was higher
approximately three times than normal kidney tissues (p>0.05).

Conclusion: miR-1267 could have
oncogenic function, have predictive value for RCC development and be predictive
about aggressiveness in ccRCC.

Anahtar Kelimeler

miR-1267, ccRCC, platelet/lymphocyte ratio, high calcium level

Destekleyen Kurum

Scientific Research Projects Commission of Ordu University

Proje Numarası

HD-1718

Kaynakça

• Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128.
• Barrey E, Saint-Auret G, Bonnamy B, Damas D, Boyer O, Gidrol X. Pre-microRNA and mature microRNA in human mitochondria. PLoS One 2011; 6: e20220.
• Cho S, Jang I, Jun Y, Yoon S, Ko M, Kwon Y, et al. MiRGator v3. 0: a microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res 2012; 41: D252-D57.
• Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009; 60: 167-79.
• Kowalczyk AE, Krazinski BE, Godlewski J, Grzegrzolka J, Kiewisz J, Kwiatkowski P, et al. SATB1 is Down-regulated in Clear Cell Renal Cell Carcinoma and Correlates with miR-21-5p Overexpression and Poor Prognosis. Cancer Genomics Proteomics 2016; 13: 209-17.
• Moch H. An overview of renal cell cancer: pathology and genetics. Semin Cancer Biol 2013; 23(1): 3-9
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-30.
• Park TJ, Cho YH, Chung HS, Hwang EC, Jung SH, Hwang JE, et al. Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer. Springerplus 2016; 5(1):1889.
• Protzel C, Maruschke M, Hakenberg OW. Epidemiology, aetiology, and pathogenesis of renal cell carcinoma. Eur Urol Suppl 2012; 11: 52-59.
• Shingarev R, Jaimes EA. Renal cell carcinoma: new insights and challenges for a clinician scientist. Am J Physiol Reanl Physiol 2017; 313: F145-F54.
• Simonnet H, Alazard N, Pfeiffer K, Gallou C, Béroud C, Demont J et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002; 23: 759-68.
• Wang Z, Peng S, Wang A, Xie H, Guo L, Jiang N, Niu Y. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma. Clin Chim Acta 2018; 480: 166-72.
• Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther 2014; 13: 3086-97.
• Zhang H, Guo Y, Shang C, Song Y, Wu B. miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer. Urology, 2012; 80: 1298-302.
• Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Euro Urol 2015; 67: 519-30.